Distinct survival benefit possible with low steroid dosesResults of Eastern Cooperative Oncology Group Phase III clinical trial E4A03 for multiple myeloma show significantly improved overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone. This finding was reported by S. Vincent Rajkumar, M.D. at the American Society of Hematology’s annual meeting.

Presently, lenalidomide and high-dose dexamethasone, referred to as Rev/Dex, is prescribed as a second-line myeloma treatment.

Dr. Rajkumar said that the finding is a major advance for treating cancer besides offering a new direction to the researchers to explore that more is not necessarily better.